4-methoxy-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine-5-carbonitrile | 57071-71-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 吡咯并嘧啶核苷和核苷酸
• 英文名称: 4-methoxy-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine-5-carbonitrile
• 英文别名: 4-methoxy-7-β-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile；7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-4-methoxy-pyrrolo[2,3-d]pyrimidine-5-carbonitrile；7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-methoxypyrrolo[2,3-d]pyrimidine-5-carbonitrile
• CAS: 57071-71-3
• 化学式: C₁₃H₁₄N₄O₅
• 分子量: 306.278
• InChiKey: XLEAGPSRYCFDSX-QYVSTXNMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  134
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-氨基-5-氰基-7-(beta-d-呋喃核糖)吡咯并[2,3-d]嘧啶 在 吡啶 、 甲醇 、 氨 、 水 、 溶剂黄146 、 sodium nitrite 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 36.5h， 生成 4-methoxy-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine-5-carbonitrile
  参考文献：
  名称：

  Synthesis of pyrrolo[2,3-d]pyrimidine nucleoside derivatives as potential anti-HCV agents

  摘要：

  Several Toyocamycin (4) analogues were examined for their ability to inhibit HCV RNA in a replicon assay. Among the compounds examined 4-methylthio (18) and 5-carboxamide oxime derivatives (23 and 27) of Toyocamycin were found to have good activity and selectivity. (c) 2006 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.bioorg.2006.07.003

文献信息

• [EN] DEAZAPURINE NUCLEOSIDE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] ANALOGUES DE NUCLEOSIDES DE DEAZAPURINE ET UTILISATION DE CEUX-CI EN TANT QU'AGENTS THERAPEUTIQUES
  申请人：RIBAPHARM INC

  公开号：WO2003061576A2

  公开（公告）日：2003-07-31

  Methods, compositions, and uses for various deazapurine nucleoside libraries and library compounds are provided. Particularly preferred deazapurine nucleosides include 7-deazapurine nucleosides, 7-deaza-8-azapurine nucleosides, toyocamycin nucleoside analogs, 3-deazapurine nucleosides, and 9-deazapurine nucleosides, while preferred uses especially inlcude use of such compounds as pharmacological, and particularly antiviral agents.